Results 121 to 130 of about 58,749 (205)

Assessment of Polymyxin B with Sodium Deoxycholate Sulfate Micelles in a Rat Model to Combat Polymyxin Nephrotoxicity. [PDF]

Antibiotics (Basel)
Bintang MAKM, Nopparat J, Srichana T.
europepmc   +1 more source

Variations in ventricular distribution of polymyxin B following intraventricular administration in patients with central nervous system infections. [PDF]

Antimicrob Agents Chemother
Jiang H, Hu Y, Cai J, Zhang J, Chen M, Hu L, Yu X, Wei K, Dai H, Yan W.   +9 more
europepmc   +1 more source

Safety and therapeutic potential evaluation of Cefotaxime plus Polymyxin B against polymyxin-carbapenem resistant Klebsiella pneumoniae in a murine model. [PDF]

PLoS One
Sturaro MC, Damaceno NDS, de Souza GHA, Echeverria JES, Cornelius EB, Pires LP, Silva PVDB, Gomes BMC, Fraga TL, Silva ON, Rossato L, Simionatto S.   +11 more
europepmc   +1 more source

A plant-derived antimicrobial peptide with multiple mechanisms of action exhibiting antibacterial and antibiofilm activities comparable to or superior to polymyxin B. [PDF]

Curr Res Microb Sci
Al Bouni MA, Lima RM, Jenei S, Tiricz H, Tímár E, Domonkos I, Kondorosi É, Endre G.   +7 more
europepmc   +1 more source

Status of Antibiotic Susceptibility of Polymyxin B And Colistin in the Treatment of Carbapenem Resistant Gram Negative Bacterial Infections: An Observational Study. [PDF]

JNMA J Nepal Med Assoc
Bhattarai AK, Pokharel K, Shrestha MV.
europepmc   +1 more source

Phage resistance of Bordetella avium due to an altered cell wall results in increased susceptibility to the polypeptide antibiotics colistin and polymyxin B. [PDF]

Sci Rep
Serian D, Churin Y, Hammerl JA, Jung A, Yue M, Müller A, Kehrenberg C.   +6 more
europepmc   +1 more source

Evaluation of antioxidant co-therapy for polymyxin B-associated nephrotoxicity and mortality: a real-World retrospective cohort study. [PDF]

J Pharm Policy Pract
Qi J, Yin Z, Peng Y, Zhang F, Li Y, Xia X, Jia X.   +6 more
europepmc   +1 more source

Therapeutic Monitoring of Polymyxin B in Critically Ill Patients with Carbapenem-Resistant Organisms: Evaluation Based on Steady-State Trough and Peak Concentrations. [PDF]

Drug Des Devel Ther
Yang J, Zhao Y, Xie L, Gan Y, Yu M, Yang G, Chen Y.   +6 more
europepmc   +1 more source

Optimizing Polymyxin B Therapy in Critical Care: Pharmacokinetic Insights and Clinical Outcomes in a Retrospective Cohort Study. [PDF]

Infect Dis Ther
Peng Q, Li Q, Xiong M, Bi M, Hu L, He J, Zhong S, Liu S, Wang H, Zhang C, Xie J, Huang Y.   +11 more
europepmc   +1 more source